Clinical Trial

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Protocol Amendment History 3 changes
notable Enrollment reduced: 160 -> 104 participants 2026-08-11
notable Trial sites expanded: 97 -> 100 locations 2026-05-19
notable Trial sites expanded: 93 -> 97 locations 2026-04-16
Trial Details
NCT Number NCT06660394
Lead Sponsor Longboard Pharmaceuticals
Conditions Dravet Syndrome
Enrollment 104 participants
Start Date 2024-09-25
Primary Completion 2026-08-21 (estimated)
Study Completion 2026-10-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-10